Good
Mostly Aligned
Patient Risk:
Low
Summary
The evaluation generally distinguishes label-supported bleeding risks from Tylenol PM and acetaminophen claims that the supplied ELIQUIS label sections do not address. However, it cites indication sections and a contraindication that are not included in the supplied material, so those assertions cannot be verified here.
Category Scores
Accurate Statements
The NSAID evaluation is appropriately classified as partially supported.
Sections 5.2 and 7.3 state that NSAID use increases bleeding risk with ELIQUIS, but the supplied text does not name ibuprofen or naproxen.
The acetaminophen and Tylenol PM findings should not be interpreted as evidence of compatibility or safety.
The supplied label sections do not address acetaminophen or Tylenol PM, so they do not establish compatibility or safety.
The hepatic-impairment evaluation is appropriately limited.
Section 8.7 gives information about ELIQUIS use in hepatic impairment but does not address Tylenol PM or acetaminophen.
ELIQUIS carries a serious bleeding warning.
Section 5.2 states that ELIQUIS increases bleeding risk and can cause serious, potentially fatal bleeding.
The evaluation generally distinguishes label-supported bleeding risks from claims not addressed by the supplied ELIQUIS label sections.
Sections 5.2, 7.3, 8.7, and 17 support the limited bleeding-risk and hepatic-impairment points; the supplied sections do not discuss Tylenol PM, acetaminophen, antihistamines, falls, or alcohol.
Unsupported Statements
Active pathological bleeding is a contraindication (section 4).
Section 4 is not supplied, so this classification cannot be verified from the provided label text. Section 5.2 does say to discontinue ELIQUIS in patients with active pathological hemorrhage, but does not label it a contraindication in the supplied excerpt.
Sections 1.1–1.4 describe prevention or treatment of specified thromboembolic events.
The supplied material includes only the heading for section 1, not the text of subsections 1.1–1.4; their specific indications cannot be verified here.
Contradictions
Important Omissions
The report should distinguish the supplied section 5.2 instruction to discontinue ELIQUIS in active pathological hemorrhage from the unverified assertion that active pathological bleeding is a contraindication.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluation appropriately avoids treating absent label information as evidence that Tylenol PM is safe with ELIQUIS and recognizes label-supported bleeding risks. Its unsupported contraindication statement should be corrected, but it does not directly recommend a potentially unsafe regimen.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
It asserts that active pathological bleeding is a contraindication and cites indication subsections that are not included in the supplied label material.
Suggested Improvement
Limit conclusions to supplied sections: state that section 5.2 directs discontinuation for active pathological hemorrhage, and avoid asserting details from sections 4 or 1.1–1.4 unless their text is provided.